Falsetti L, Mazzani M D, Rubessa S, Ruggeri C
Dept. of Obstetrics and Gynecology, University of Brescia, Italy.
Acta Eur Fertil. 1992 Jan-Feb;23(1):29-32.
Evaluation of clinical intra- and post-operative benefits of pre-myomectomy therapy with a Gonadotropin-Releasing Hormone Agonist (GnRH-A) (Goserelin) in anemic and non-anemic patients suffering from uterine leiomyomas. Evaluation of ultrasound, estradiol (E2) and hematological measurements before and during treatment with a GnRH-a in thirty women with uterine leiomyomas, comparing pre-treated patients operative time, total intraoperative blood loss, blood counts and febrile morbidity with of thirty-five control women. GnRH-A pre-treatment cures, iron-deficiency anemia, significantly reduces myoma and uterine volume (p < 0.01), total intra-operative blood loss (p < 0.001), decreases post-operative febrile morbidity, though it does not reduce operative time. GnRH-A pre-treatment over a period no longer than two months should be suggested in anemic patients suffering from uterine leiomyomas who have to undergo myomectomy.
评估促性腺激素释放激素激动剂（GnRH-A）（戈舍瑞林）在子宫肌瘤患者术前治疗中对贫血和非贫血患者的临床术中及术后益处。对30例子宫肌瘤患者在使用GnRH-a治疗前和治疗期间进行超声、雌二醇（E2）和血液学测量，并将预处理患者的手术时间、术中总失血量、血细胞计数和发热发病率与35例对照女性进行比较。GnRH-A预处理可治愈缺铁性贫血，显著减小肌瘤和子宫体积（p<0.01），减少术中总失血量（p<0.001），降低术后发热发病率，但不缩短手术时间。对于必须接受肌瘤切除术的子宫肌瘤贫血患者，建议进行不超过两个月的GnRH-A预处理。
